Navigation Links
Silencing hepatitis B virus prevent recurrence of liver cancer
Date:6/24/2010

(PHILADELPHIA) Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

The standard of care for patients with HCC is local ablation of the tumor, unless it is large or has metastasized. However, HCC tumors often recur, or new lesions develop. In the International Journal of Cancer, Hie-Won Hann, M.D., professor of Medicine at Jefferson Medical College of Thomas Jefferson University, and colleagues reported that the median survival in patients who received antiviral therapy after HCC diagnosis was 60 months in patients. In those who did not receive antiviral therapy, the median survival was 12.5 months.

"Before the antiviral drugs were developed, patients would often develop new lesions within a few months of tumor ablation because we were not treating the underlying virus that is causing the liver cancer," Dr. Hann said. "The virus drives the cancer, and by suppressing the virus and making it undetectable we can extend the survival for these patients."

The small study included 15 CHB patients who received local ablation of a single HCC tumor that was less than four cm. The first six patients were diagnosed between 1991 and 1997, prior to the development of antiviral therapy. These patients were considered historical controls.

The other nine patients were diagnosed between 2000 and 2004. These patients began ongoing antiviral therapy with lamivudine immediately after HCC diagnosis. Other antiviral medications, such as tenofovir and adefovir were added to the regimen if resistance to lamivudine developed, or even without drug resistance.

All patients who received the antiviral therapy maintained undetectable hep
'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NVHR: Administrations 2011 Budget Proposal Shortchanges Five Million Americans Afflicted with Chronic Viral Hepatitis
2. NVHR Issues Challenge to Administration, Congress: Dont Leave 5 Million Americans Afflicted with Chronic Viral Hepatitis Out in the Cold with Budget Freeze
3. New Treatment Eyed for Hepatitis C
4. Treatment for chronic hepatitis C: A phase II study
5. New Hepatitis C Treatment Shows Promise
6. NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus
7. Hepatitis B Foundation awards UT School of Public Health professor
8. Key to Hepatitis C May Be Two Cellular Proteins
9. IOM report recommends steps to tackle hepatitis B and C
10. New screening system for hepatitis C
11. Groundbreaking research to find vaccine for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... McLean, Va. (PRWEB) September 16, 2014 ... use through predictive analytics and targeted clinical programs, ... The announced changes support the Company’s drive to ... analytics and targeted clinical programs. On September 2, ... parent company, Millennium Health, announced that RxAnte founder ...
(Date:9/16/2014)... News) -- Illegal drug use among teens in the United ... report. Encouragingly, the new study also found that ... among young people between the ages of 12 and 17 ... of 70,000 people aged 12 and older across the United ... abuse problems among this age group also dropped from 8.9 ...
(Date:9/16/2014)... YORK, NY (September 16, 2014) The Columbia ... the 2014 Higher Education Excellence in Diversity (HEED) ... and largest diversity-focused publication in higher education. As ... honor recognizing U.S. colleges and universities that demonstrate ... be featured along with 82 other recipients in ...
(Date:9/16/2014)... September 15, 2014A prospective study that compared patient-reported ... with bone metastases demonstrates that single fraction radiation ... fraction radiation therapy (MFRT) when pain, function and ... presented today at the American Society for Radiation ... indicates that improvements in patients, pain, function and ...
(Date:9/16/2014)... September 16, 2014 Fresh shiitake ... iron and potassium. They are second-most consumed mushroom ... and their healing and health properties. , In ... Shiitakes can stimulate and strengthen the immune system ... contain polycharrides, including beta glucans . These ...
Breaking Medicine News(10 mins):Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3
... ULURU Inc. (NYSE AMEX: ULU ) ... 31, 2009. The Company reported a net loss of $3.1 ... $1.8 million, or $0.03 per share, for the same period last ... cash equivalents of $5.1 million, compared with $7.6 million at December ...
... Calif., May 15 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, ... former chief operating officer of Boston Scientific, to its ... shareholders at the company,s annual shareholders, meeting on May ...
... Richard Boland, M.D., chief of gastroenterology at Baylor ... vice president of the American Gastroenterological Association (AGA) Institute, ... 2011. The oldest medical specialty society in the United ... and practice of gastroenterology. AGA membership includes 16,500 physicians ...
... & PARIS, FRANCE The International Union for ... Public Health Education (SOPHE) are pleased to release today ... standards and quality assurance systems of global capacity in ... Health Education & Behavior (Vol. 36, No. 3, ...
... of Ultrasound in Medicine is pleased to announce the ... All operators of ultrasound systems with an output display ... consists of 3 parts: Bioeffects and Biophysics, Prudent Use, ... the information from this 64 page publication, users can ...
... Group, Inc. (Nasdaq: NYER ) reported results for ... for third quarter of fiscal 2009 increased $1.3 million or ... the comparable quarter in the prior year. The increase ... new pharmacies over the past 12 months. Revenues slightly ...
Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2009 Financial Results 6Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 2Health News:Thoratec Announces Appointment of Paul LaViolette to Board of Directors 3Health News:Dallas Gastroenterologist Named Vice President of Prestigious National Organization 2Health News:Special journal issues released on global health promotion and health education 2Health News:AIUM releases second edition of 'Medical Ultrasound Safety' 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 3Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 4Health News:Nyer Medical Group, Inc. Reports Revenues of $18.6 Million for the Quarter Ended March 31, 2009 5
(Date:9/16/2014)... , Sept. 16, 2014 Based ... closure market, Frost & Sullivan recognises Incisive Surgical ... for Customer Value Leadership. Incisive Surgical,s uniquely-designed, innovative ... technology that eliminates the need for patients to ... and staple removal  that may result in increased ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... HARTLAND, Wis., Aug. 30, 2011 H&P Industries, Inc., ... hiring of Eamonn Vize to fill the Chief Operating ... 20 years of experience in the Pharmaceutical and Biotechnology ... provide his knowledge of Pharmaceutical Operations and Validations to ...
... , a leading supplier of embedded technologies, products, and ... embedded computers to a medical original equipment ... of the six-month contract is about 1.5M USD. ... will allow the customer to meet market demand and ...
Cached Medicine Technology:Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application 2
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: